3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Neoplasms
6
Carcinoma, Non-Small-Cell Lung
6
Heart Diseases
3
Vascular Diseases
2
Small Cell Lung Carcinoma
2
Cardiovascular Diseases
2
Cardiotoxicity
2
Triple Negative Breast Neoplasms
1
Recurrence
1
Rectal Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Cancer Resectable
1
Ovarian Carcinosarcoma
1
Neoplasms, Second Primary
1
Myelodysplastic Syndromes
1
Metabolic Diseases
1
Leukemia, Myeloid, Acute
1
Leukemia, Monocytic, Acute
1
Immune-related Adverse Event
1
Hematologic Neoplasms
1
Heart Failure
1
Esophageal Neoplasms
1
Drug-Related Side Effects and Adverse Reactions
1
Colorectal Neoplasms
1
Colorectal Cancer Metastatic
1
Carcinoma, Hepatocellular
1
Cancer Therapy-related Cardiovascular Toxicity
1
Breast Neoplasms
1
Advanced Ovarian Cancer
1
Interventions
Cyclophosphamide
361
Trastuzumab
352
Paclitaxel
304
Docetaxel
272
Letrozole
221
Capecitabine
221
Carboplatin
185
Doxorubicin
181
Tamoxifen
157
Radiotherapy
154
Epirubicin
145
Fulvestrant
143
Anastrozole
139
Surveys and Questionnaires
132
Exercise
128
pertuzumab
113
Vinorelbine
110
Blood Specimen Collection
109
exemestane
106
palbociclib
104
Bevacizumab
104
pembrolizumab
98
Magnetic Resonance Spectroscopy
97
Albumin-Bound Paclitaxel
87
Gemcitabine
84
Drug Therapy
83
Lapatinib
78
130-nm albumin-bound paclitaxel
72
Neoadjuvant Therapy
71
Cisplatin
69
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Breast Neoplasms
×
Antineoplastic Agents
×
Clear all
NCT03591276
2020-10-23
KEYDOX
Shaare Zedek Medical Center
Phase 1/2
Recruiting
15 enrolled